检索结果-内蒙古大学图书馆

The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023

引用

Transplantation and Cellular Therapy 2024年第2期30卷 S375-S376页

作者： Atallah, Rawan Saif, Md Saiful Islam Danai, Dima Shrestha, Anuj Anwer, Faiz Mushtaq, Muhammad Umair Lutfi, Forat Shune, Leyla Hashmi, Hamza Ganguly, Siddhartha MD, MD, FACP McGuirk, Joseph P, DO Atrash, Shebli Abdallah, Al-Ola Banerjee, Rahul, MD Ahmed, Nausheen Logan, Emerson US Myeloma Innovations Research Collaborative (USMIRC) Kansas City KS Division of Hematologic Malignancies & Cellular Therapeutics Kansas University Medical Center Kansas City KS Department of Biostatistics & Data Science University of Kansas Medical Center Kansas City KS Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland OH Hematology and Oncology University of Missouri At Kansas City Kansas MO Blood and Marrow Transplant Program Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland OH Division of Hematologic Malignancies & Cellular Therapeutics University of Kansas Medical Center Westwood KS Department of Hematology-Oncology Medical University of South Carolina Charleston SC Hematology Houston Methodist Hospital and Neal Cancer Center Houston TX University of Kansas Medical Center Westwood KS Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute/Atrium Health Charlotte NC Fred Hutchinson Cancer Center Seattle WA

IntroductionDespite promising efficacy and safety profiles of BCMA-directed cellular therapies (BDCT) for multiple myeloma (MM), limited access is a challenge. This survey gains insights into the practices and perspectives of oncologists from BDCT-referring and treating centers and identify potential areas of improvement. MethodsThe survey was developed in collaboration with USMIRC with input from BDCT-prescribing and referring oncologists. “ BDCT centers” included CART and TCE-Centers where these respective therapies were administered, while others were grouped as “BDCT-referring centers” including “CART/ TCE- referring centers”. Interim Analysis is described. ResultsThe survey was sent to 247 oncologists of which 66 (27%) responded and 37(15%) completed. 73% of oncologists were from academic centers, and 54% treated plasma cell disorders only. 70% were from CART-centers and 81% were from TCE- centers. 11% of centers offered only TCE while none exclusively offered CART alone. Among CART-centers, 54% offered both ide-cel/cilta-cel. Oncologists practiced in the Midwest (43%), South (22%), West (19%), and Northeast (16%). Choice of BDCT in Real-World Scenarios: TCE was the favored BDCT for patients meeting criteria but with either significant comorbidity, renal failure, poor performance status, mild cognitive impairment, age >75yr, rapidly progressive disease, or post-CART relapse. CART was preferred for scenarios of extramedullary disease, allogeneic stem cell transplant recipients, and renal failure on dialysis. Respondents ranked choices of potential barriers to access as below ( Figure 1) Barriers to CART access: Financial burden was the top-ranking barrier (45%) from CART-referring centers, while the number of production slots allocated per month was the top barrier (69%) from CART-centers. Relocation and caregiver requirements were ranked as top barriers by 27% from CART- referring centers and none from CART-centers. Barriers to TCE access: Among oncologists fro

关键词：

来源：评论

学校读者我要写书评

暂无评论

Association of Risk Factors For Venous Thromboembolism and Overall Survival in Lung cancer

Blood Vessels, Thrombosis & Hemostasis

引用

Blood Vessels, Thrombosis & Hemostasis 2025年

作者： Thomas E. Plate Asaad Trabolsi Rachel S. Kronenfeld Leticia E. Campoverde Dan Morgenstern-Kaplan Alyssa J. Mercadel Michael Caballero Wei Zhao Gerald A. Soff Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami Fl USA Hematology Oncology Fellowship Program Jackson Memorial Health System/ University of Miami Miami Fl USA Division of Pediatric Hematology/Oncology University of Miami/Jackson Memorial Hospital Miami FL Internal Medicine Residency program division of internal medicine Department of Medicine University of Miami/ Jackson Memorial Hospital Miami Division of Gynecologic Oncology Department of Obstetrics Gynecology and Reproductive Sciences University of Miami Leonard M. Miller School of Medicine Miami Data Science and Engineering UHealth Information Technology University of Miami Miami FL Biostatistics and Bioinformatics Shared Resource Sylvester Comprehensive Cancer Center University of Miami Miami FL Division of Hematology Department of Medicine University of Miami Miller School of Medicine Miami Fl USA

Venous thromboembolism (VTE) is a frequent complication in patients with lung cancer, but the risk factors and incidence in different lung cancer subtypes have not been fully characterized. Despite multiple studies supporting the use of VTE prophylaxis in patients with cancer at increased risk of VTE by the Khorana score (KS), routine use of VTE prophylaxis is uncommon in clinical practice for these patients. This study further characterizes the risk factors and incidence of VTE and in patients with lung cancer at a university cancer center. Further, we assessed the association of KS and its individual components with overall survival in this same group of patients with lung cancer. Utilizing natural language processing and human review to detect thrombotic events in the electronic medical record, a 12-month incidence of 10.1% was identified in the 632 lung cancer patients analyzed. Significant risk factors included age <60 years and white blood cell count (WBC) ≥ 11× 10 9 /L, but KS itself was not significantly associated with VTE. The median overall survival was 12 months with VTE. The KS, age ≥ 60 years, stage III-IV, WBC ≥ 11× 10 9 /L, Hgb <10 gm/dL, BMI, surgery and VTE were identified as significant predictors of death. These findings warrant further validation, as the KS and two of its individual components in this study of lung cancer were significantly associated with reduced overall survival.

关键词： Lung cancer thrombosis Khorana Score cancer associated thrombosis

来源：评论

学校读者我要写书评

暂无评论

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses

引用

Annals of Oncology 2024年 35卷 S749-S749页

作者： J. Chan S. Geyer T. Zemla M.V. Knopp S.C. Behr S. Pulsipher J. Acoba A. Shergill E.M. Wolin T.R. Halfdanarson B. Konda N. Trikalinos S. Shaheen N. Vijayvergia N.A. Dasari J. Strosberg E.C. Kohn M. Kulke E.M. O'Reilly J. Meyerhardt Department of Medical Oncology Dana-Farber Cancer Institute Boston MA USA Alliance Statistics and Data Management Center Mayo Clinic Rochester MN USA Wright Center of Innovation & IROC University of Cincinnati Cincinnati OH USA Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco CA USA Clinical and Translational Science Section Cancer Biology Program University of Hawaii Cancer Center Honolulu HI USA Department of Medicine - Section of Hematology/Oncology University of Chicago Chicago IL USA Department of Hematology-Oncology Icahn School of Medicine at Mount Sinai New York NY USA Medical Oncology Department Mayo Clinic Rochester MN USA Division of Medical Oncology The Ohio State University Comprehensive Cancer Center Columbus OH USA Division of Oncology Washington University School of Medicine in St. Louis - Siteman Cancer Center St. Louis MO USA Division of Oncology Stanford Comprehensive Cancer Institute Stanford CA USA Department of Hematology/Oncology Fox Chase Cancer Center - Main Campus Philadelphia PA USA Department of Gastrointestinal Medical Oncology MD Anderson Cancer Center Houston TX USA Department of GI Oncology H. Lee Moffitt Cancer Center & Research Institute Tampa FL USA CTEP National Cancer Institute Bethesda MD USA Section of Hematology & Medical Oncology Boston University and Boston Medical Center Boston MA USA Department of Medicine Memorial Sloan Kettering Cancer Center New York NY USA

来源：评论

学校读者我要写书评

暂无评论

Author Correction: ASS1 metabolically contributes to the nuclear and cytosolic p53-mediated DNA damage response

引用

Nature metabolism 2024年第7期6卷 1417页

作者： Lisha Qiu Jin Lim Lital Adler Emma Hajaj Leandro R Soria Rotem Ben-Tov Perry Naama Darzi Ruchama Brody Noa Furth Michal Lichtenstein Elizabeta Bab-Dinitz Ziv Porat Tevie Melman Alexander Brandis Sergey Malitsky Maxim Itkin Yael Aylon Shifra Ben-Dor Irit Orr Amir Pri-Or Rony Seger Yoav Shaul Eytan Ruppin Moshe Oren Minervo Perez Jordan Meier Nicola Brunetti-Pierri Efrat Shema Igor Ulitsky Ayelet Erez Department of Molecular Cell Biology Weizmann Institute of Science Rehovot Israel. Department of Medicine D Beilinson Hospital Petah Tikva Israel. Telethon Institute of Genetics and Medicine Pozzuoli Italy. Department of Immunology and Regenerative Biology Weizmann Institute of Science Rehovot Israel. Department of Molecular Neuroscience Weizmann Institute of Science Rehovot Israel. Department of Biochemistry and Molecular Biology The Institute for Medical Research Israel-Canada Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel. Department of Life Sciences Core Facilities Weizmann Institute of Science Rehovot Israel. The De Botton Protein Profiling Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine Weizmann Institute of Science Rehovot Israel. Cancer Data Science Lab Center for Cancer Research National Cancer Institute National Institute of Health Bethesda MD USA. Department of Translational Medicine Medical Genetics University of Naples Federico II Naples Italy. Scuola Superiore Meridionale (SSM School of Advanced Studies) Genomics and Experimental Medicine Program University of Naples Federico II Naples Italy. Department of Molecular Cell Biology Weizmann Institute of Science Rehovot Israel. ayelet.erez@weizmann.ac.il.

来源：评论

学校读者我要写书评

暂无评论

Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma

引用

Blood 2024年 144卷 645-645页

作者： Nicholas J. Haradhvala Stephanie Yiu Sam Sadigh Laura Beckmann Amber Pospistle Stephanie Deng Santiago Rivero Yao Yu Yeo Katie Maurer Vignesh Shanmugam McKayla Van Orden Wesley S Lu Shuqiang Li Kenneth J. Livak Huaying Qiu Yuzhou Chang Ankit Basak Alex K Shalek Mikaela M. McDonough Robert A. Redd Erin M. Parry Broad Institute of MIT and Harvard Cambridge MA Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Boston MA Wyss Institute at Harvard Boston MA Department of Pathology Brigham and Women's Hospital Boston MA Harvard Medical School Boston MA Department of Medical Oncology Dana-Farber Cancer Institute Boston MA Faculty of Medicine and Cologne University Hospital Department I of Internal Medicine Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf University of Cologne Cologne Germany Cologne Germany Program in Virology Harvard Medical School Boston Translational Immunogenomics Lab Dana-Farber Cancer Institute Boston MA Center for Virology and Vaccine Research Beth Israel Deaconess Medical Center Boston The Ohio State University Columbus Institute for Medical Engineering & Science and Department of Chemistry Massachusetts Institute of Technology Cambridge Ragon Institute of Mass General MIT and Harvard Boston MA Institute for Medical Engineering & Science and Department of Chemistry Massachusetts Institute of Technology Cambridge MA Dana-Farber Cancer Institute Boston MA Department of Data Science Dana-Farber Cancer Institute Boston MA

Histologic transformation of follicular lymphoma (FL) to an aggressive lymphoma (transformed FL [tFL]) is a common disease complication associated with poor clinical outcomes. However, understanding of the mechanisms that drive FL transformation and the associated lymph node (LN) tumor microenvironment (TME) reorganization remains limited. To define the remodeling that occurs at tFL, we performed single-cell and spatial dissection of clinical samples over the process of transformation. To identify immune cell populations and malignant B cells, single-cell RNA sequencing (scRNA-seq) was applied to >47,300 malignant and 24,000 non-malignant cells across 10 LN biopsies (4 tFL, 6 FL). tFL samples displayed reduced plasmacytoid (pDCs) and follicular dendritic cells (FDCs) (FDR-corrected Wilcoxon rank sum q=0.13). Bulk RNA-seq analysis of biopsy samples from 18 independent patients with relapsed/refractory disease (5 FL, 13 tFL) confirmed FL and tFL transcriptomes were distinct by principal components (PC) analysis (Hotelling t 2 test on first two PCs p=0.0018), with high expression of myeloid genes ( CD163, FCGR3A, CES1 ) and low expression of the FDC gene FDCSP as the top tFL-enriched PC. Decreased FDC and pDCs in tFL, as well as increased fibroblastic reticular cells (FRCs) and monocytes (FDR-corrected Wilcoxon rank sum q<0.1), were detected by CIBERSORTx deconvolution. As orthogonal validation of our findings in a larger independent cohort, we performed spatial transcriptomics (GeoMx) and proteomics (CODEX, Co-detection by Indexing) across 2 tissue microarrays (TMAs). We localized cell populations from our discovery analysis in the LN TME through acquiring 70 unique GeoMx regions of interest derived from 52 biopsies (33 FL,19 tFL; 9 were paired FL-tFL). Each was subjected to 4 samplings (CD3+ T cells, PAX5+ tumor cells, CD68+ macrophages and other cells). tFL was confirmed to display alterations in LN cell types that establish follicle organization through cell-intera

关键词：

来源：评论

学校读者我要写书评

暂无评论

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

引用

Annals of Oncology 2023年 34卷 S848-S849页

作者： D. Planchard J.R. Brahmer J.C-H. Yang H.R. Kim R.K. Li J-Y. Han D.L. Cortinovis Y. Runglodvatana E. Nakajima A. Ragone M. Winter M. Gustavson Department of Medical Oncology Institut Gustave Roussy Villejuif France Thoracic Oncology Program The Johns Hopkins Kimmel Cancer Center Baltimore MD USA Medical Oncology Department National Taiwan University Hospital Taipei City Taiwan Department of Internal Medicine Division of Medical Oncology Yonsei Cancer Center Seoul Republic of Korea Medical Oncology Department St. Luke's Medical Center - Quezon City Quezon City Philippines Center for Lung Cancer National Cancer Center - Graduate School of Cancer Science and Policy Goyang Republic of Korea SC Oncologia Medica Fondazione IRCCS San Gerardo dei Tintori Monza Italy Division of Medical Oncology Vajira Hospital - Faculty of Medicine - Navamindradhiraj University Bangkok Thailand Late Development Oncology R&D AstraZeneca Gaithersburg MD USA Late Development Oncology R&D AstraZeneca Mississauga ON Canada Data Science and Quantitative Biology AstraZeneca Cambridge UK Translational Medicine Oncology R&D AstraZeneca Gaithersburg MD USA

来源：评论

学校读者我要写书评

暂无评论

Frequency of Deleterious Pathogenic/Likely Pathogenic Germline Variants in Related and Unrelated Allogeneic Hematopoietic Cell Transplant Donors for Patients with Myelodysplastic Syndrome

引用

Transplantation and Cellular Therapy 2025年第2期31卷 S113-S113页

作者： Stubbins, Ryan J. Hattig, Zachary S. Trottier, Amy M. Rodgers, Courtnee V. Haribabu, Yoga Crone, Lara Govaerts, Inge Smith, William, MD Juckett, Mark Grunwald, Michael R. Oran, Betul, MD, MS Elmariah, Hany Villa, Kennia Auer, Paul Kim, Soyoung Dong, Jing Chen, Zhongyuan Parrilla, Charimar Santiago Zhang, Tao Bolon, Yung-Tsi Spellman, Stephen R., MBS Saber, Wael Godley, Lucy A., MD, PhD Leukemia/ Bone Marrow Transplant Program of British Columbia Vancouver BC Canada Robert H. Lurie Comprehensive Cancer Center and Northwestern University Chicago IL Division of Hematology Department of Medicine Dalhousie University Halifax NS Canada Department of Pathology Dalhousie University Halifax NS Canada Department of Pathology Wayne State University School of Medicine Detroit MI Division of Hematology Oncology and Transplantation University of Minnesota Minneapolis MN Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Atrium Health NC Levine Cancer Institute Charlotte NC Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston TX Blood and Marrow Transplantation and Cellular Immunotherapy H. Lee Moffitt Cancer Center and Research Institute Tampa FL CIBMTR® (Center for International Blood and Marrow Transplant Research) NMDP Minneapolis MN Division of Biostatistics Data Science Institute and Cancer Center Medical College of Wisconsin Milwaukee WI CIBMTR® (Center for International Blood and Marrow Transplant Research) Department of Medicine Medical College of Wisconsin Milwaukee WI Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine Medical College of Wisconsin Milwaukee WI Division of Biostatistics Institute for Health and Equity and Cancer Center Medical College of Wisconsin Milwaukee WI Cancer Center Biostatistics Shared Resource Medical College of Wisconsin Milwaukee WI Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL

IntroductionUp to 15% of myelodysplastic syndrome (MDS) patients have pathogenic (P) or likely pathogenic (LP) germline variants (PGVs) underlying their disease. PGVs in allogeneic hematopoietic cell transplant (allo-HCT) donor cells may impact outcomes. Around 5% of related donors (RDs) share PGVs with recipients, the rate of PGVs in unrelated donors (UDs) is unknown. ObjectiveWe quantified PGVs in recipient-donor pairs for patients undergoing RD or UD allo-HCT for MDS. MethodsPaired peripheral blood samples from MDS patients undergoing allo-HCT and RDs or UDs underwent 30X whole genome sequencing (WGS) in prior CIBMTR studies. Variants were called in 40 hematologic cancer predisposition genes. Quality filtered variants were culled by a 0.005 gnomAD allele frequency (AF) cutoff, adjusted to 0.05 for genes with high AF P/LP variants ( CHEK2, DDX41). Intronic variants were removed, except in genes with known P/LP intronic variants ( DKC1, FANCI, GATA2, NF1, TERT). Variants with >25 somatic occurrences in COSMIC were removed. P/LP variants were manually curated for pathogenicity per established guidelines. Shared PGVs in RD and recipients were confirmed germline. PGVs in UD and recipients were considered likely germline if variants known to have minimal somatic variation. ResultsTotal 494 patients with paired recipient-donor WGS were included, 97 patients had RDs and 397 patients had UDs as their stem cell source. PGVs were found in 15% (75/494) of recipients with MDS, most commonly in DDX41 (20%, 15/75), RUNX1 (17%, 13/75), and CHEK2 (8%, 6/75). In RDs, 5% (5/97) of donors had PGVs. The PGV was shared between the donor and recipient in 80% (4/5) of cases and in 20% (1/5), the recipient lacked the donor PGV. Among UDs, 4% (16/397) had PGVs identified. In 19% (3/16) of UDs with a PGV the recipient had a separate, unshared PGV (Table 1). ConclusionWe identified PGVs in a significant number of allo-HCT donors for MDS patients, with similar rates in RDs as prior literatur

关键词：

来源：评论

学校读者我要写书评

暂无评论

Identification of Frailty Clusters Using Cross-Sectional Frailty and Frailty Trajectory: Cohort of Heart Failure Veterans

JACC: Advances

引用

JACC: Advances 2025年第5期4卷 101751页

作者： Razjouyan, Javad Tofighi, Saeed Orkaby, Ariela R. Bozkurt, Biykem Sharafkhaneh, Amir Horstman, Molly J. Goyal, Parag Amos, Christopher I. Intrator, Orna Naik, Aanand D. VA HSR&D Center for Innovations in Quality Effectiveness and Safety Michael E. DeBakey VA Medical Center Houston TX United States Department of Medicine Baylor College of Medicine Houston TX United States Big Data Scientist Training Enhancement Program VA Office of Research and Development Washington DC United States Tehran Heart Center Cardiovascular Diseases Research Institute Tehran University of Medical Sciences Tehran Iran New England Geriatrics Research Education and Clinical Center VA Boston Health Care System Boston MA United States Brigham & Women's Hospital Harvard Medical School Boston MA United States Division of General Internal Medicine Department of Medicine Weill Medical College of Cornell University New York NY United States Division of Cardiology Department of Medicine Weill Medical College of Cornell University New York NY United States Department of Internal Medicine UNM Comprehensive Cancer Center University of New Mexico Albuquerque NM United States Brookdale Department of Geriatrics & Palliative Medicine Icahn School of Medicine at Mount Sinai New York NY United States Geriatrics & Extended Care Data Analysis Center James J. Peters VA Medical Center Bronx NY United States Department of Management Policy and Community Health The University of Texas Health Science Center at Houston (UTHealth) Houston TX United States UTHealth Institute on Aging University of Texas Health Science Center Houston TX United States

Background: Frailty is a syndrome associated with increased vulnerability and diminished physiological reserves. Three-quarters (78%) of heart failure (HF) patients are frail. Traditional frailty indices (FIs) assess cross-sectional deficits, while frailty trajectories (FTs) measure changes over time. Objectives: This study aims to examine the interaction between FI and FT to enhance risk stratification in hospitalized adults with HF. Methods: This retrospective cohort study utilized data from the Veterans Health Administration, including 143,687 veterans aged >50 admitted for HF from 2005 to 2019. FT measurements were derived from FI calculations for each of the 3 years before index hospitalization. Unsupervised clustering identified 4 clusters based on FI and FT interactions: low-low, low-high, high-low, and high-high. Associations between these clusters and clinical outcomes (ie, 1-year mortality, prolonged hospital stays, emergency department visits, and readmissions) were analyzed. Results: The study cohort was mostly older (mean age 74 ± 10 years), male (98%), and diverse (55% non-Hispanic White). Survival analysis showed distinct mortality risks across clusters;while the 2 clusters with low FI had the longest survival, the high-high group had the lowest survival probability. Adjusted logistic regression indicated that the high-high cluster had over twice the odds of 1-year mortality compared to the low-low cluster (OR: 2.29;95% CI: 2.15-2.44). The high-high cluster also had significantly higher rates of prolonged hospital stays, emergency department visits, and readmissions at 30 and 90 days postdischarge. Conclusions: Integrating cross-sectional FI and longitudinal FT offers a comprehensive assessment of frailty in HF patients, improving risk stratification and disease management. © 2025

关键词： cluster analysis frailty heart failure patient outcome risk assessment

来源：评论

学校读者我要写书评

暂无评论

A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

引用

Transplantation and Cellular Therapy 2024年第2期30卷 S207-S208页

作者： Wesson, William, MPH Dima, Danai Davis, James, PharmD, BCOP Rashid, Aliya Furqan, Fateeha, MD Saif, Md Saiful Islam Logan, Emerson, BS McGann, Mary, PharmD, BCOP Tabak, Carine Hazlett, Liz, PharmD Lutfi, Forat Mushtaq, Muhammad Umair, MD Hoffmann, Marc, MD Abdallah, Al-Ola Anwer, Faiz Hamadani, Mehdi McGuirk, Joseph P, DO Hashmi, Hamza Ahmed, Nausheen University of Kansas Medical Center Westwood KS US Myeloma Innovations Research Collaborative (USMIRC) Kansas City KS Rochester General Hospital Rochester NY Department of Biostatistics & Data Science University of Kansas Medical Center Kansas City KS University of Kansas School of Medicine Kansas City KS Department of Pharmacy Medical University of South Carolina (MUSC) Charleston SC University of Kansas Cancer Center Kansas City KS Division of Hematologic Malignancies and Cellular Therapeutics Kansas University Medical Center Kansas City KS Division of Hematologic Malignancies & Cellular Therapeutics University of Kansas Medical Center Westwood KS Blood and Marrow Transplant Program Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland OH BMT & Cellular Therapy Program Medical College of Wisconsin Milwaukee WI The Medical University of South Carolina (MUSC) Charleston SC

BackgroundThe US Food and Drug Administration implemented a Risk Evaluation and Mitigation Strategy/REMS program for all currently approved BCMA and CD19-directed chimeric antigen receptor T-cell (CAR-T) therapies to mitigate the risks of CRS and ICANS by requiring patients (pts) to stay in proximity of the authorized treating center (ATC) for a period of 4 weeks. Relocation and long monitoring period may present a potential financial challenge and increase disparities in access. Defining the optimal duration of monitoring after treatment, has not been described previously. We therefore evaluated real-world safety outcomes of BCMA and CD-19 CAR-T recipients for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). MethodsPts with MM and NHL who received BCMA CART: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), or CD19 CART: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), lisocabtagene maraleucel (liso-cel) and brexucabtagene autoleucel (brexu-cel) respectively, from 12/2017 to 06/2023, at four centers: University of Kansas Medical Center, Medical University of South Carolina, University of Wisconsin Health University Hospital, and the Cleveland Clinic Foundation were included. There were two groups: those with no CRS/ICANS or first CRS/ICANS before Day 7 (Events< D7) and those with CRS/ICANS ≥ Day 7 (Events ≥ D7). Chi-square test and proportion tests were calculated. Results256 pts including 106 MM (86% ide-cel, 14% cilta-cel) and 150 NHL pts (61% axi-cel, 21% tisa-cel, 12% liso-cel, 7% brexu-cel) were included. Most patients (64%) lived beyond 30 minutes of the ATC. Most (85%) were in the Events

关键词：

来源：评论

学校读者我要写书评

暂无评论

REDUCING INTER-OBSERVER VARIABILITY IN ENDOMYOCARDIAL BIOPSY ASSESSMENT

引用

Journal of Pathology Informatics 2022年 13卷 100058-100058页

作者： Lipkova, Jana Chen, Tiffany Y. Lu, Ming Y. Chen, Richard J. Shady, Maha Williams, Mane Wang, Jingwen Noor, Zahra Mitchell, Richard N. Mahmood, Faisal Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA Broad Institute of Harvard and MIT Cambridge MA USA Data Science Program Dana-Farber Cancer Institute Boston MA USA Harvard-MIT Health Sciences and Technology Cambridge MA USA Department of Biomedical Informatics Harvard Medical School Boston MA USA

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：